ESMO Asia Congress 2023: Abstracts

View the abstracts in the online programme

The abstract submission system is now closed

Abstract submission deadlines

*A preliminary abstract indicating the data expected to be available by the LBA deadline must be submitted online by 22 August 2023 as an “intent to submit a late-breaking abstract”.

Outcome notifications

Outcome notifications are expected to be made available to first authors and submitters by early October.

Outcome notifications of accepted full LBAs are expected to be made available to first authors and submitters by end-October. 

Information for presenters

Detailed instructions for the preparation of slide presentations and/or posters will be made available by early October in the section “Information for Presenters”. 

Abstract submission categories

• Breast cancer, early stage
• Breast cancer, locally advanced
• Breast cancer, metastatic
• Developmental therapeutics
• Gastrointestinal tumours, colorectal
• Gastrointestinal tumours, non-colorectal
• Genitourinary tumours, non-prostate
• Genitourinary tumours, prostate
• Gynaecological cancers
• Haematological malignancies
• Head and neck cancer, excluding thyroid
• Miscellaneous
• Palliative care
• Precision medicine
• Supportive care
• Thoracic tumours, early stage
• Thoracic tumours, locally advanced
• Thoracic tumours, metastatic

Late-breaking abstracts (LBA)

Late-breaking abstracts may be submitted for high quality, new research findings from randomised phase II or phase III trials with implications for clinical practice or understanding of disease processes.

The final late-breaking abstract deadline of date is under no circumstances to be considered as an extension of the general submission deadline.

Trial in Progress abstracts

Trial in Progress abstracts (TiPs) in all phases of clinical research (phases I to III) may be submitted to ESMO Asia Congress 2023.

It is expected that abstracts submitted as Trial in Progress are ongoing trials that have not reached any protocol-specified endpoints for analysis.

Young Oncologist (YO) Patient case studies

Challenging clinical case studies in the new era of personalised medicine may be submitted by young oncologists under 40 years of age.

Presentation and publication of accepted abstracts

The ESMO Asia 2023 Scientific Committee will select abstracts for presentation during the Congress based on the following possibilities:

• Presidential Symposium – Oral presentations by authors presenting cutting-edge and significant clinical practice-changing studies, followed by expert discussion and perspectives.
• Proffered Paper – Oral presentations by authors presenting original data of superior quality, followed by expert discussion and perspectives.
• Mini Oral – Short oral presentations by authors presenting data of good quality, followed by expert discussion and perspectives.
• Poster – Display session for review, discussion and questions. The presenting authors must be available for Q&A to represent their work.

All accepted abstracts, including late-breaking abstracts, will be published online in the ESMO Asia Congress 2023 Abstract Book, a supplement to the official ESMO journal, Annals of Oncology, except from YO Patient case studies.

Publication schedule of accepted abstracts

Details regarding the publication of accepted abstracts will be available here.

ESMO Merit Travel Grants 

A limited number of ESMO Merit travel grants to ESMO Asia Congress 2023 are available, upon application, to first authors (= presenter) who submit abstracts considered to be deserving of recognition. Candidates must be ESMO Members under the age of 40. Selection will be made by the ESMO Asia Congress 2023 Scientific Committee on a competitive basis from among the accepted abstracts.

The application is now closed.